ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Vascular surgery · Ann Vasc Surg · 2026-08-06

Meta-analysis of 13 studies of endovascular treatment for moderate-to-severe calcified femoropopliteal disease: pooled 12-month primary patency 83.8% and freedom from clinically driven TLR 90.7%. Stent, atherectomy and lithotripsy subgroups were descriptive only, not comparative.

Meta-analysisn = 13 studies
Wang et al. Clinical Efficacy of Different Endovascular Approaches in Femoropopliteal Artery Disease with Moderate-to-Severe Calcification: A Meta-Analysis
Vascular surgery · J Vasc Surg · 2026-08-03

Systematic review and meta-analysis of 2 RCTs (n=387) and 19 observational studies in PAD endovascular revascularisation: IVUS vs angiography guidance likely reduces restenosis (RR 0.59; moderate certainty) but may not reduce reintervention or mortality in trials.

Meta-analysisn = 1,164,716
d'Entremont et al. Intravascular ultrasound versus angiography for lower-extremity peripheral artery disease endovascular revascularization: A systematic review and meta-analysis
Vascular surgery · J Vasc Surg · 2026-08-03

Meta-analysis of 17 studies (5290 patients, 5492 limbs) with chronic limb-threatening ischaemia: GLASS III vs I was associated with higher mortality (HR 1.28), MALE (HR 1.36) and patency loss (HR 2.23); in GLASS III, endovascular vs bypass had higher MALE (HR 1.88).

Meta-analysisn = 5,290
Melo et al. A systematic review and meta-analysis of prognosis and revascularization strategies in chronic limb-threatening ischemia according to the global limb anatomical staging system
Vascular surgery · Eur J Vasc Endovasc Surg · 2026-07-14

ESVS 2026 guidelines on vascular graft and endograft infection (VGEI), updating the 2020 version, issue 81 graded recommendations covering definitions, diagnosis, multidisciplinary care, antimicrobial therapy, intracavity and extracavity management, and follow up.

Guideline
Lejay et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2026 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections
Vascular surgery · Ann Vasc Surg · 2026-07-14

Meta-analysis of 7 RCTs (712 patients) with symptomatic PAD: revascularisation plus supervised exercise improved maximum walking distance vs either alone (MD 106 m; 95% CI 47–166). No clear effect on ABI, SF-36 physical score or reintervention; high risk of bias.

Meta-analysisn = 712
Marchand et al. Evaluating the Added Value of Combined Revascularization and Supervised Exercise Therapy in Symptomatic Peripheral Artery Disease: A Systematic Review and Meta-Analysis with a Focus on Functional and Patient-Reported Outcomes
Vascular surgery · Ann Vasc Surg · 2026-07-14

Meta-analysis of 10 observational studies (50,242 patients) with CLTI undergoing revascularisation: diabetes was associated with higher mortality (HR 1.23) and major amputation (HR 1.43); amputation risk was significant only at ≥3 years, with substantial heterogeneity.

Meta-analysisn = 50,242
Estevam et al. Impact of Diabetes on Outcomes after Lower Limb Revascularization in Patients with Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis
Vascular surgery · J Vasc Surg · 2026-05-22

Systematic review of 10 observational studies (5794 participants): elevated Lp(a) was associated with PAD prevalence (pooled OR 1.81). After lower-extremity revascularisation, in only 2 cohorts, it was linked to major adverse limb events (OR 5.09) and major amputation (OR 2.62).

Meta-analysisn = 5,794
Mwipatayi et al. A systematic review and meta-analysis of elevated lipoprotein(a) and adverse limb outcomes in peripheral artery disease after revascularization
Vascular surgery · Eur J Vasc Endovasc Surg · 2026-05-18

ESVS focused guideline update for intermittent claudication: paclitaxel coated balloons and stents may be considered only for selected re-stenosis, after discussing uncertain long term safety; SWEDEPAD 2 showed no quality of life or re-intervention benefit at 12 months.

Guideline
Nordanstig et al. Editor's Choice - Focused Update on Paclitaxel Coated Technologies, from the 2024 European Society for Vascular Surgery (ESVS) Guidelines on the Management of Asymptomatic Peripheral Arterial Disease and Intermittent Claudication
Vascular surgery · Ann Vasc Surg · 2026-05-12

Phase 3 trial of REX-001 bone marrow cell therapy in diabetic patients with no-option chronic limb-threatening ischaemia, stopped early for lack of efficacy at interim analysis: ulcer healing or Rutherford improvement in 28.6% vs 27.3% with placebo (32 completed).

RCTn = 32
Peeters et al. The Premature Termination of the Phase III SALAMANDER Trial of REX-001, an Autologous Bone Marrow Cell Therapy, for Chronic Limb Ischemia in Diabetic Patients: Insights and Outcomes
Vascular surgery · J Vasc Surg · 2026-04-30

In a trial of 290 patients with peripheral arterial disease having groin incisions for arterial surgery (275 analysed), closed incisional negative-pressure wound therapy did not reduce wound complications versus standard dressing (P=.37); 25.5% overall had complications.

RCTn = 290
Lenselink et al. Closed incisional negative-pressure wound therapy vs standard surgical dressing for groin incisions following arterial vascular surgery: A prospective multicenter randomized clinical trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.